ABBV News 54.19 06/20/2014 04:21:38 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 54.19 $ABBV

NDA Resubmission, Accelerated Assessment of Marketing Application, and Esteemed Recognition - Analyst Notes on McKesson, AbbVie, Lilly, Zoetis and Salix
PR Newswire - 21 mins ago
Today, Analysts Review released its analysts' notes regarding McKesson Corporation (NYSE: MCK), AbbVie Inc. (NYSE: ABBV), Eli Lilly and Company (NYSE: LLY), Zoetis Inc. (NYSE: ZTS) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3930-100free.

Shire Confirms Rejection of AbbVie Proposal
PR Newswire - 59 mins ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire - Thu Jun 19, 10:48PM CDT
AbbVie Inc. ("AbbVie" notes the recent press speculation and confirms it made an indicative approach to Shire plc ("Shire" with a merger proposal which was rejected by the Board of Shire. There can be no certainty that any firm offer will be made. Discussions are no longer ongoing.

Better Stock Today Challenge: Philip Morris vs. AbbVie
Mark Reeth and David Williamson, The Motley Fool - Motley Fool - Thu Jun 19, 12:20PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Philip Morris International    takes on ...

AbbVie (ABBV) Declares 42c Quarterly Dividend
at The Street - Thu Jun 19, 10:50AM CDT
AbbVie (ABBV) declares a quarterly dividend of 42 cents a share, payable August 15 to shareholders of record as of July 15.

AbbVie Declares Quarterly Dividend
PR Newswire - Thu Jun 19, 10:28AM CDT
The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share.

Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec   and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...

Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.

Merck Backs Out of Endocyte Vintafolide Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 11:10AM CDT
Endocyte, Inc. (ECYT) announced that it has regained worldwide rights to oncology candidate, vintafolide, as Merck decided to discontinue its investment in the development of vintafolide.

Androgel Testosterone Lawsuit Website Launches at AndrogelTestosteroneLawsuits.com by Prominent National Product Safety Law Firm
PRWeb - Wed Jun 18, 3:05AM CDT
The Androgel Testosterone Lawsuits website is a new resource from national product and family safety attorneys at The Onder Law Firm. Based in St. Louis, these testosterone lawyers have also represented clients in major pharmaceutical, product liability, and personal injury lawsuits, and offer expertise in representing the interests of individuals and families against major corporations. Persons seeking information about filing an Androgel testosterone lawsuit related to heart attack or stroke may contact the firm for a free testosterone lawsuit case review through the new website.

Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi.  Sovaldi raked in a reported...

GW Pharma Up On Positive Data For Epilepsy Drug
at Investor's Business Daily - Tue Jun 17, 3:20PM CDT
British biotech GW Pharmaceuticals (GWPH) Tuesday reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, sending the stock up 16% to 89.82 on the stock market today . But shares gave up some of those...

Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the...

2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).

AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:50PM CDT
AbbVie's (ABBV) experimental hepatitis C virus treatment could gain approval early in the fourth quarter of 2014.

Better Stock Today Challenge: Bank of America Corp vs. AbbVie
David Hanson and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 11:22AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Bank of America  takes on  AbbVie  for this...

Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 10:40AM CDT
Gilead Sciences (GILD) announced encouraging results from a phase III study on its HCV combination therapy of ledipasvir and Sovaldi .

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings -
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 334

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 333

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 282

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 546

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 466

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 289

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 335

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Announces Record Q4 Results and Product Launches

Updated Category News Views 236

Apple Achieves Remarkable Fourth Quarter Results Apple Inc. has announced its financial performance for the fourth quarter of its fiscal year 2024, showcasing stellar results that reflect the company's growth and expansion in the tech industry. The tech giant reported quarterly revenue hitting a staggering $94.9 billion, which represents a 6% increase compared to the...

Continue Reading
China-Russia Culture Fair Boosts Jiamusi, Heilongjiang

Updated Category News Views 100

Jiamusi: A Cultural Crossroad in Northeast China Imagine this: Jiamusi, nestled in the embrace of Heilongjiang Province, stepping into the spotlight as it co-hosts the 16th China-Russia culture fair. This northeast city isn't just another dot on the map. It's gearing up to be a hub of cultural buzz, packed with ties that go beyond borders. From July through September,...

Continue Reading
Unlocking Sustainability in Broadband Using Existing Networks

Updated Category News Views 176

Unlocking Sustainability in Broadband Using Existing Networks LUND, Sweden — InCoax Networks has introduced a groundbreaking whitepaper addressing the modernization of broadband infrastructure in multi-dwelling units (MDUs). This initiative is not only cost-effective but also significantly improves the environmental impact associated with deploying broadband services....

Continue Reading
Interlink Electronics Secures NASA Grant for Air Quality Solutions

Updated Category News Views 174

Interlink Electronics Receives Significant Funding from NASA Recognizes Company's leading position in gas sensor research and commercialization Interlink Electronics, Inc. (NASDAQ: LINK), a premier provider of innovative sensors and electronic solutions, has received a significant boost with a $150,000 award from NASA. This funding is designated for the development of...

Continue Reading
Burford Capital Set to Reveal 3Q24 Financial Insights Soon

Updated Category News Views 154

Burford Capital Set to Release 3Q24 Financial Results Burford Capital Limited, renowned for its leadership in finance and asset management focused on legal services, has announced the date for its financial results. The firm is poised to share critical insights regarding its performance for the three and nine months ending September 30, 2024. Details of the Financial...

Continue Reading